NASDAQ:ACOR

Acorda Therapeutics, Inc Earning Date

USA |NASDAQ |USD

ACOR Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 1, 2021 Sep 2021 $-1.56 $-2.29 $0.30
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 1, 2021 Sep 2021 $30.57M $31.79M $53.09M

Acorda Therapeutics, Inc's next earnings date is Monday, Nov 1, 2021 for the fiscal quarter ending Sep 2021.

ACOR Earnings Date & History Chart

ACOR Earnings & Revenue Forecast

ACOR Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 1 $-1.11 $-1.11 $-1.11
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 1 $-7.64 $-7.64 $-7.64
Dec 2022 1 $-0.96 $-0.96 $-0.96

ACOR Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-1.11 $-1.11 $-1.11
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-7.64 $-7.64 $-7.64
Dec 2022 0 / 0 $-0.96 $-0.96 $-0.96

ACOR Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 1 $31.01M $31.01M $31.01M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 1 $120.38M $120.38M $120.38M
Dec 2022 1 $120.51M $120.51M $120.51M

ACOR Earnings Date & Revenue History

ACOR Earnings History

|
Show More
Show More

ACOR Revenue History

|
Show More
Show More

Acorda Therapeutics, Inc Next Earnings Date & Report

ACOR Next Earnings Date & Report Preview: Sep 2021 (FQ)

ACOR's next earnings date is Monday, Nov 1, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 1 analysts, the average EPS estimation for Acorda Therapeutics, Inc's next quarterly earnings is $-1.56, with a low EPS estimation of $-1.56, and a high estimation of $-1.56.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-1.56, the last 2 month trend is $-1.56, and the 3 month trend is $-1.56.

Based on 1 analysts, the average revenue estimation is $30.57M, with a low revenue estimation of $30.57M, and a high estimation of $30.57M.

Acorda Therapeutics, Inc Previous Earnings Dates & Reports

ACOR Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Acorda Therapeutics, Inc's previous earnings date was Aug 5, 2021 for its fiscal quarter ended Jun 30, 2021.

ACOR's earnings per share (EPS) was $-2.29, missing the consensus analysts forecast of $-2.09 by -9.57%.

The EPS was higher than the previous fiscal quarter (Mar 2021) by -35.13%, and lower than the same period a year before (Jun 2020) by 3.15%.

Revenues were $31.79M, better than the forecast of $31.79M by 0.00%, up by 10.13% from the previous quarter , and down by -5.45% from the same period last year.

The company reported a net income of $-22.86M.

Free cash flow for the quarter was $-8.82M , compared to $-26.94M last quarter and $-22.75M a year before.

ACOR ended the quarter with $187.07M in total debt, a decrease of -26.03% compared to the previous quarter, and a decrease of -19.59% compared to the same quarter a year before.

ACOR Previous Earnings Date & Report Recap: Dec 2020 (FY)

Acorda Therapeutics, Inc's previous annual earnings date was Mar 4, 2021 for its fiscal year ended Dec 31, 2020.

ACOR's earnings per share (EPS) was $-12.58, missing the consensus analysts forecast of $-7.91 by 59.04% , and higher than the previous year's EPS (Dec 2019) by -63.54%.

Revenues were $152.97M, better than the forecast of $148.81M by 2.79%, and down by -20.50% from previous year's revenue.

The company reported a net income of $-99.59M.

Acorda Therapeutics, Inc reported a free cash flow of $-65.40M for its fiscal year, compared to $-218.59M a year ago.

The company ended the fiscal year with $251.36M in total debt, an increase of 9.37% compared to the previous year.